Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Histologically or cytologically confirmed recurrent or metastatic Squamous Cell
             Carcinoma of the Head and Neck (SCCHN). All primary sites are eligible excluding WHO
             type III or EBV nasopharyngeal (WHO type I and WHO type II allowed as long as they are
             EBV negative)

          -  ECOG performance status 0-1

          -  Adequate organ and marrow function as defined below. Laboratory tests should be
             completed within 14 days prior to registration: ANC greater than or equal to
             1,500/mm3, Platelets greater than or equal to 100,000/mm3, HgB greater than 9g/dL
             (acceptable to reach this by transfusion), Total bilirubin less than or equal to
             1.5mg/dL, Albumin greater than 2.5 g/dL, AST(SGOT)/ALT(SGPT) less than or equal to
             2.5X institutional upper limit of normal, alkaline phosphatase less than or equal to
             2.5 x upper limit of normal, GFR greater than 30 mL/min (by standard Cockroft and
             Gault formula or measured via 24 hour urine collection)

          -  Women of childbearing potential (WOCBP) with negative serum or urine pregnancy test
             within 7 days of D1 of treatment

          -  WOCBP and men must agree to use adequate contraception prior to study entry and for
             duration of treatment under this protocol; adequate contraception is defined as any
             medically recommended method (or combination of methods) per standard of care.

          -  Cancer must be considered incurable by the treating clinician

          -  Ability to understand and willingness to sign a written informed consent document

        Exclusion Criteria:

          -  History of prior cumulative exposure to > 300mg/m2 cisplatin, AUC of 18 of
             carboplatin, or their combined equivalent within one year prior to enrollment

          -  Surgery or radiation within the four weeks prior to D1 of treatment under this
             protocol

          -  Prior systemic chemotherapy unless it was part of definitive-intent (curative intent)
             treatment more than 6 months before study entry

          -  Other active, invasive malignancy requiring ongoing therapy or expected to require
             systemic therapy within two years; localized squamous cell carcinoma of the skin,
             basal-cell carcinoma of the skin, carcinoma in-situ of the cervix, or other
             malignancies requiring locally ablative therapy only will not result in exclusion

          -  Pregnant or lactating female